WallStreetZenWallStreetZen

NYSEMKT: ATNM
Actinium Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Actinium Pharmaceuticals revenue was $90.00k for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $90.0k, up Infinity% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ATNM annual revenue was $0.0, with -100% growth year-over-year.

ATNM past revenue growth

How has ATNM's revenue growth performed historically?

Company
11.11%
Industry
284.61%
Market
22.91%
ATNM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ATNM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ATNM's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ATNM revenue history

Current Revenue
$90.0k
Current Earnings
-$34.6M
Current Profit Margin
-38,443.3%

Be the first to know when ATNM announces revenue.

ATNM Revenue History By Year

ATNM Yearly RevenueATNM RevenueATNM ChangeATNM Revenue Growth
2024-12-31$0.00-$81.00k-100.00%
2023-12-31$81.00k-$949.00k-92.14%
2022-12-31$1.03M-$114.00k-9.97%
2021-12-31$1.14MN/AN/A
2020-12-31$0.00N/AN/A
2019-12-31$0.00N/AN/A
2018-12-31$0.00N/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00N/AN/A
2011-12-31$0.00N/AN/A

1 of 1

Actinium Pharmaceuticals Revenue FAQ

What was ATNM's revenue last quarter?

On Invalid Date, Actinium Pharmaceuticals (NYSEMKT: ATNM) reported Q3 2025 revenue of $90.00 thousand up Infinity% year over year. In the same quarter last year, Actinium Pharmaceuticals's revenue was $0.00.

What was Actinium Pharmaceuticals's revenue in 2024?

Actinium Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $0.00, a 100% decrease year over year.

How much does Actinium Pharmaceuticals make in a day?

Based on Actinium Pharmaceuticals annual revenue for the past five years, ATNM makes an average of $1,235.62 per day.

What was Actinium Pharmaceuticals's annual revenue growth in the past year?

As of Q4 2025, Actinium Pharmaceuticals's revenue has grown 11.11% year over year. This is 273.5 percentage points lower than the US Biotechnology industry revenue growth rate of 284.61%. Actinium Pharmaceuticals's revenue in the past year totaled $90.00 thousand.

How much does Actinium Pharmaceuticals make in a year?

Actinium Pharmaceuticals's revenue by year for the past five years is:
  • Actinium Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $0.00, a 100% decrease year over year.
  • Actinium Pharmaceuticals's annual revenue for Dec 31, 2023 was $81.00 thousand, a 92.14% decrease from 2022.
  • Actinium Pharmaceuticals's annual revenue for 2022 was $1.03 million, a 9.97% decrease from 2021.
  • Actinium Pharmaceuticals's annual revenue for 2021 was $1.14 million, a Infinity% increase from 2020.
  • Actinium Pharmaceuticals's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.